204 related articles for article (PubMed ID: 16483175)
21. Improvement of acromegaly after octreotide LAR treatment.
Mangupli R; Lisette A; Ivett C; Paul C; de los Ríos Victoria C; Luis CJ
Pituitary; 2003; 6(1):29-34. PubMed ID: 14674721
[TBL] [Abstract][Full Text] [Related]
22. Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly.
Fahlbusch R; Kleinberg D; Biller B; Bonert V; Buchfelder M; Cappabianca P; Carmichael J; Chandler W; Colao A; George A; Klibanski A; Knopp E; Kreutzer J; Kundurti N; Lesser M; Mamelak A; Pivonello R; Post K; Swearingen B; Vance ML; Barkan A
Pituitary; 2017 Dec; 20(6):668-675. PubMed ID: 28825168
[TBL] [Abstract][Full Text] [Related]
23. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
24. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
25. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.
Lindsay JR; Harding JA; Ellis PK; Sheridan B; Atkinson AB
Pituitary; 2003; 6(4):209-14. PubMed ID: 15237932
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response.
Luque-Ramírez M; Portoles GR; Varela C; Albero R; Halperin I; Moreiro J; Soto A; Casamitjana R;
Horm Metab Res; 2010 Jan; 42(1):38-44. PubMed ID: 19798622
[TBL] [Abstract][Full Text] [Related]
27. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
Oki Y; Inoue T; Imura M; Tanaka T; Genma R; Iwabuchi M; Hataya Y; Matsuzawa Y; Iino K; Nishizawa S; Nakamura H
Endocr J; 2009; 56(9):1095-101. PubMed ID: 19755754
[TBL] [Abstract][Full Text] [Related]
28. Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
Chin SO; Chung CH; Chung YS; Kim BJ; Kim HY; Kim IJ; Kim JG; Kim MS; Kim SY; Lee EJ; Lee KY; Kim SW
BMJ Open; 2015 Jun; 5(6):e006898. PubMed ID: 26063564
[TBL] [Abstract][Full Text] [Related]
29. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
30. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
[TBL] [Abstract][Full Text] [Related]
31. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
[TBL] [Abstract][Full Text] [Related]
33. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
34. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
35. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).
Stewart PM; Stewart SE; Clark PM; Sheppard MC
Clin Endocrinol (Oxf); 1999 Mar; 50(3):295-9. PubMed ID: 10435053
[TBL] [Abstract][Full Text] [Related]
36. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
Shen M; Shou X; Wang Y; Zhang Z; Wu J; Mao Y; Li S; Zhao Y
Endocr J; 2010; 57(12):1035-44. PubMed ID: 21099129
[TBL] [Abstract][Full Text] [Related]
37. Octreotide LAR for the treatment of acromegaly.
Vallette S; Serri O
Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):783-93. PubMed ID: 18611118
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.
Ayuk J; Stewart SE; Stewart PM; Sheppard MC;
Clin Endocrinol (Oxf); 2004 Mar; 60(3):375-81. PubMed ID: 15009004
[TBL] [Abstract][Full Text] [Related]
40. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]